• 1
    World Health Organization. Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates. World Health Organization, Geneva, 1995. WHO/GPA/STD 95.1 Rev 1.
  • 2
    Birley H, McDonald P, Carey P. High-level ciprofloxacin resistance in Neisseria gonorrhoeae. Genitourin. Med. 1994; 70: 2923.
  • 3
    Centers for Disease Control and Prevention. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones-Ohio and Hawaii, 1992–1994. Morb. Mortal. 1994; 43: 3257.
  • 4
    Grasden WR, Warren CA, Phillips I, Hodges M, Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990; 335: 51.
  • 5
    Jephcott AE, Turner A. Ciprofloxacin resistance in gonococci. Lancet 1990; 335: 165.
  • 6
    Kam KM, Wong PW, Cheung MM, Ho NKY, Lo KK. Quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Sex. Transm. Dis. 1996; 23: 1036.
  • 7
    Corkill JE, Percival A, Lind M. Reduced uptake of ciprofloxacin in a resistant strain of Neisseria gonorrhoeae and transformation of resistance to other strains. J. Antimicrob. Chemother. 1991; 28: 6014.
  • 8
    Deguchi T, Yasuda M, Asano M et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 1995; 39: 5613.
  • 9
    Deguchi T, Yasuda M, Nakano M et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alternations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob. Agents Chemother. 1996; 40: 10203.
  • 10
    Tanaka M, Kumazawa J, Matsumoto T, Kobayashi I. High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitoriun. Med. 1994; 70: 903.
  • 11
    Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 1994; 14: 37180.
  • 12
    Tanaka M, Otsuki M, Nishino T, Kobayashi I, Matsumoto T, Kumazawa J. Mutation in DNA gyrase of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae. Genitourin. Med. 1996; 72: 2957.
  • 13
    Tanaka M, Sakuma S, Takahashi K et al. Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro. Sex. Transm. Infect. 1998; 74: 5962.
  • 14
    Shigemura K, Shirakawa T, Okada H et al. Mutations in gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex. Transm. Dis. 2004; 31: 1804.
  • 15
    Trees DL, Sandul AL, Peto-Mesola V et al. Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and United States. Int. J. Antimicrob. Agents 1999; 12: 32532.
  • 16
    National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th edn. Approved Standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
  • 17
    National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Informational Supplement. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
  • 18
    Li Z, Yokoi S, Kawamura Y, Maeda S, Ezaki T, Deguchi T. Rapid detection of quinolone resistance-associated gyrA mutations in Neisseria gonorrhoeae with a Lightcycler. J. Infect. Chemother. 2002; 8: 14550.
  • 19
    Lyamichev V, Brow MAD, Dahlberg JE. Structure-specific endonucleolytic cleavage of nucleic acids by eubacterial DNA polymerase. Science 1993; 260: 77883.
  • 20
    Shi MM, Myrand SP, Bleavins MR, De La Iglesia FA. High throughtput genotyping for the detection of a single polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. J. Clin. Pathol. 1999; 52: 2959.